Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yizi Jin
Observed name:
Jin, Yizi
Institutions:
Shanghai Medical College of Fudan University,
Shanghai Jiao Tong University,
Fudan University,
Renji Hospital,
Fudan University Shanghai Cancer Center,
Shanghai Cancer Institute
show all 6
Observed institutions:
Shanghai Medical College of Fudan University,
Shanghai Jiao Tong University,
Fudan University,
Renji Hospital,
Soochow University,
Fudan University Shanghai Cancer Center,
Shanghai Cancer Institute
show all 7
ORCID:
0000-0001-7425-8264
Observed ORCID:
0000-0001-7425-8264
OpenAlex ID:
A5030307586
NF-κB in biology and targeted therapy: new insights and translational implications
2024
·
Qing Guo
, Yizi Jin
, et al.
·
Signal Transduction and Targeted Therapy
·
2,612
PDF
NF-κB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges
2024
·
Qing Guo
, Yizi Jin
, et al.
·
Life Sciences
·
57
Diagnostic and grading accuracy of 18F-FDOPA PET and PET/CT in patients with gliomas: a systematic review and meta-analysis
2019
·
Jiarui Xiao
, Yizi Jin
, et al.
·
BMC Cancer
·
49
PDF
Clinicopathological evidence of hepatitis B virus infection in the development of gastric adenocarcinoma
2019
·
Hongxia Cui
, Yizi Jin
, et al.
·
Journal of Medical Virology
·
39
HER2‐low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis
2023
·
Mingxi Lin
, Ting Luo
, et al.
·
Cancer
·
36
PDF
Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients
2022
·
Haitao Miao
, Yuyun Sun
, et al.
·
Frontiers in Oncology
·
25
Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
2020
·
Mingxi Lin
, Yang Chen
, et al.
·
Journal of Cancer
·
25
PDF
Overcoming matrix barriers for enhanced immune infiltration using siRNA-coated metal-organic frameworks
2025
·
Cheng Zeng
, Xiaojing Chen
, et al.
·
Acta Biomaterialia
·
16
Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis
2023
·
Huiyue Li
, Jennifer K. Plichta
, et al.
·
Breast Cancer Research and Treatment
·
16
PDF
A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple‐negative breast cancer
2020
·
Mingxi Lin
, Yizi Jin
, et al.
·
Cancer Medicine
·
14
PDF
Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases
2022
·
Mingxi Lin
, Yizi Jin
, et al.
·
International Journal of Cancer
·
11
PDF
Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer
2021
·
Mingxi Lin
, Yizi Jin
, et al.
·
Therapeutic Advances in Medical Oncology
·
11
Inflammatory Myofibroblastic Tumor of Spinal Canal: Brief Case Report
2020
·
Maciej Bryl
, Jan Fortuniak
, et al.
·
Journal of Neurological Surgery Part A Central European Neurosurgery
·
7
Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor‐positive, HER2 ‐negative metastatic breast cancer: A real‐world multicenter study
2024
·
Doudou Li
, Yizi Jin
, et al.
·
Cancer Medicine
·
5
Development and validation of a nomogram for predicting overall survival of patients with cancer of unknown primary: a real-world data analysis
2021
·
Yizi Jin
, Mingxi Lin
, et al.
·
Annals of Translational Medicine
·
5
PDF
Efficacy of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer: A Real-World Retrospective Cohort Study in China
2025
·
Yuxin Yan
, Yizi Jin
, et al.
·
Breast Cancer Targets and Therapy
·
4
PDF
Expert review on systemic treatment in the St. Gallen International Breast Cancer Conference 2021
2021
·
Mingxi Lin
, Yizi Jin
, et al.
·
Translational Breast Cancer Research
·
3
PDF
Complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases
2026
·
Mingxi Lin
, Zhexu Wen
, et al.
·
Nature Communications
·
2
PDF
Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer
2026
·
Jian Zhang
, Yiqun Du
, et al.
·
MedComm
·
2
Results and exploratory biomarker analyses of a phase II study CHANGEABLE: Combination of HX008 and niraparib in germ-line-mutated metastatic breast cancer.
2024
·
Yizi Jin
, Yiqun Du
, et al.
·
Journal of Clinical Oncology
·
2
The TUBA1B–G3BP2 Axis Sustains p65 Transcriptional Activity to Promote Hepatocellular Carcinoma Progression
2026
·
Fen Lin
, Hechun Lin
, et al.
·
Advanced Science
·
1
AKAP13 regulates GLI1/ULK1 axis and drive tumor resistance to next-generation HER2-targeted therapies
2026
·
Qing Guo
, Xinyu Chen
, et al.
·
Oncogene
Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade
2026
·
Teng Zhou
, Yifei Zhu
, et al.
·
Advanced Science
Exploring the potential of postmastectomy radiotherapy in cN + and ypN0 breast cancer patients following neoadjuvant chemotherapy
2026
·
Yizi Jin
, Huiyue Li
, et al.
·
Breast Cancer Research and Treatment
Results and exploratory biomarker analyses of a phase II study CHANGEABLE: combination of HX008 and niraparib in GErm-line-mutAted metastatic breast cancer
2025
·
Yizi Jin
, Yiqun Du
, et al.
·
The Lancet Regional Health - Western Pacific
Show more works
View as search
Works count:
27
Citation count:
2,942
H-index:
11
I10-index:
12
Year
Topic
Type